Literature DB >> 16362142

The puzzle of overactive bladder: controversies, inconsistencies, and insights.

Roger R Dmochowski1.   

Abstract

Overactive bladder (OAB) affects millions of individuals and may severely impair the quality of life of those affected. The contribution of human behavior to manifestations of this symptom complex remains poorly understood. Continued evolution of our understanding of the pathophysiology of OAB has identified contributory mechanisms, which in turn may open new therapeutic avenues. Recent improvements in drug delivery systems represent advances in the management of OAB. However, more complete symptom control with greater tolerability is desirable; this awaits the development of agents specific for newly emerging and as yet unidentified pathophysiologic pathways. Importantly, as understanding of outcomes assessment in OAB matures, refined assessments of disease severity, response to intervention, and patient preference should be possible.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16362142     DOI: 10.1007/s00192-005-0032-3

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  91 in total

Review 1.  Potential therapeutic targets for treatment of the overactive bladder.

Authors:  D J Sellers; C R Chapple; R Chess-Williams
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

Review 2.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

3.  P2X receptors and their role in female idiopathic detrusor instability.

Authors:  Barry A O'Reilly; Alan H Kosaka; Gillian F Knight; Thomas K Chang; Anthony P D W Ford; Janice M Rymer; Rick Popert; Geoffrey Burnstock; Stephen B McMahon
Journal:  J Urol       Date:  2002-01       Impact factor: 7.450

4.  Impact of urinary incontinence and overactive bladder on quality of life.

Authors:  Francesca Chiaffarino; Fabio Parazzini; Maurizio Lavezzari; Vincenzo Giambanco
Journal:  Eur Urol       Date:  2003-05       Impact factor: 20.096

5.  Loss of purinergic P2X(3) and P2X(5) receptor innervation in human detrusor from adults with urge incontinence.

Authors:  K H Moore; F R Ray; J A Barden
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

6.  Which women with stress incontinence require urodynamic evaluation?

Authors:  A C Weidner; E R Myers; A G Visco; G W Cundiff; R C Bump
Journal:  Am J Obstet Gynecol       Date:  2001-01       Impact factor: 8.661

Review 7.  Urodynamic investigations for management of urinary incontinence in adults.

Authors:  C M Glazener; M C Lapitan
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 8.  Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.

Authors:  F Haab; L Stewart; P Dwyer
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096

9.  Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats.

Authors:  M J Espey; H J Du; J W Downie
Journal:  Brain Res       Date:  1998-07-06       Impact factor: 3.252

10.  American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life.

Authors:  Harriette M Scarpero; Joshua Fiske; Xiaonan Xue; Victor W Nitti
Journal:  Urology       Date:  2003-06       Impact factor: 2.649

View more
  7 in total

1.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

2.  Affective Temperament Profiles of Overactive Bladder Patients.

Authors:  Ali Saribacak; Kürşat Altinbaş; Hasan Yilmaz; Alp Özkan; Levend Özkan; Timuçin Oral
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

3.  Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year follow-up.

Authors:  Rachel Kafri; Daniel Deutscher; Jeffrey Shames; Jacob Golombp; Itshak Melzer
Journal:  Int Urogynecol J       Date:  2012-11-17       Impact factor: 2.894

4.  Urodynamic Effects of Propiverine on Detrusor Overactivity and Abdominal Straining during Voiding in Awake Rats with Intravesical Prostaglandin E(2) Instillation.

Authors:  Jun Hyung Oh; Yong Seok Lee; Long Hu Jin; Yong Hyun Kwon; Won Hee Park; Tack Lee
Journal:  Korean J Urol       Date:  2010-01-21

5.  Improving the clinical prediction of detrusor overactivity by utilizing additional symptoms and signs to overactive bladder symptoms alone.

Authors:  Bernard T Haylen; Tin Lok Chiu; Dianne Avery; Jialun Zhou; Matthew Law
Journal:  Int Urogynecol J       Date:  2014-03-25       Impact factor: 2.894

6.  Rehabilitation versus drug therapy for urge urinary incontinence: long-term outcomes.

Authors:  Rachel Kafri; Jeffrey Shames; Meir Raz; Michal Katz-Leurer
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-06-05

7.  Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?

Authors:  Axel Hegele; Sonja Knippschild; Carsten Frohme; Jörg Hänze; Peter Olbert; Rainer Hofmann
Journal:  BMC Urol       Date:  2014-11-04       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.